Tribunal rules on classification of medicines under Central Excise Tariff Act

The Tribunal ruled in favor of the appellant, M/s. Wockhardt Ltd., concluding that the medicines produced by them were not classified as patent or proprietary medicines under the Central Excise Tariff Act. The decision was based on the lack of evidence establishing a proprietary interest in the medicines, despite the presence of the manufacturer's name. The Tribunal emphasized the importance of distinguishing between a house mark and a product mark in determining the classification of medicines under the Tariff entry, referencing legal precedents to support their ruling.

---

---

Issues: Classification of medicine under Central Excise Tariff Act

Issue 1: Classification of Medicine
The appeal questioned whether the medicine produced by M/s. Wockhardt Ltd. falls under the category of patent or proprietary medicine as per the Central Excise Tariff Act or Tariff Item 14E of the erstwhile Central Excise Tariff. The appellant argued that the medicines, including Albendazole suspension and Calcium Borogluconate Oxytetracycline, were generic and not proprietary. They emphasized that the manufacturer's name was a legal requirement on the label and did not establish a trade connection. The appellant cited various legal precedents to support their stance, including decisions by the Supreme Court and High Courts.

Analysis:
The appellant contended that the medicines were generic and not proprietary, as indicated by the generic names and the legal requirement to display the manufacturer's name on the label. They argued that the presence of the manufacturer's name did not establish a trade connection, citing legal precedents to support their position. The appellant also raised concerns regarding the time limit for demanding duty, highlighting their compliance with filing classification lists and approvals received from authorities over the years. They argued that there was no suppression of facts as all relevant information was known to the department through approved classification lists and assessments.

Issue 2: Interpretation of Tariff Entry
The interpretation of the Tariff entry was crucial in determining whether the medicines in question qualified as patent or proprietary. The appellant relied on legal explanations and precedents to argue that the presence of the manufacturer's name, such as "WOCKHARDT," did not establish a proprietary interest in the medicine. They emphasized the distinction between a house mark and a product mark, citing relevant judgments to support their interpretation.

Analysis:
The Tribunal examined the legal definitions and interpretations related to patent or proprietary medicines under the Central Excise Tariff Act. They analyzed the significance of brand names, trademarks, and other marks indicating a trade connection between the medicine and the manufacturer. The Tribunal considered the conspicuous presence of the manufacturer's name on the label and cap of the medicine containers. By referencing legal precedents, including decisions by the Supreme Court and High Courts, the Tribunal concluded that the medicines in question did not qualify as patent or proprietary medicines. They emphasized the importance of establishing a proprietary interest in the medicine based on the marks and symbols used, ultimately ruling in favor of the appellant.

Conclusion:
The Tribunal, after thorough analysis and consideration of legal arguments and precedents, concluded that the medicines manufactured by M/s. Wockhardt Ltd. were not classified as patent or proprietary medicines under the Central Excise Tariff Act. They based their decision on the lack of sufficient evidence indicating a proprietary interest in the medicines, despite the presence of the manufacturer's name. The Tribunal's ruling favored the appellant, emphasizing the distinction between a house mark and a product mark in determining the classification of medicines under the Tariff entry.

---